Roche Pharmaceuticals will participate in the China International Import Expo (CIIE) for the eighth consecutive year. This year, under the theme "Innovating for Life," Roche will comprehensively showcase over 40 products and diverse innovative solutions across its entire portfolio. Among them, more than ten products covering various disease areas, including upcoming launches and future pipeline products, will make their collective debut in China, setting a new historical record. This includes the first anti-CD20 monoclonal antibody - Galenica® (Ocrelizumab) - which has shown positive results in randomized Phase III clinical trials for lupus nephritis, and PDS, the world's first and only intraocular implant as a breakthrough solution in ophthalmology. Additionally, Roche will for the first time demonstrate its end-to-end integrated pharmaceutical value chain in China, as well as provide a comprehensive overview of its newly established biopharmaceutical production facility with a total investment of 2.04 billion RMB.
Source：Medical and Health News